Welcome to the e-CCO Library!

DOP54: Identification and development of a 1st in class naturally-derived protein that drives mucosal healing and is orally delivered by an engineered cellular therapy targeting the gastro-intestinal tract
Year: 2022
Source: ECCO'22
Authors: Shilova, I.(1);La Chat, C.(1);Nigatu, E.(1);Messner, E.(1);Desnoyer, J.(1);Willcoxon, M.(1);Banas, S.(1);Ravichandar, D.(2);Narayan, N.(2);DeSantis, T.(2);Dabbagh, K.(1);Yamamoto, L.(1);
Created: Friday, 11 February 2022, 3:52 PM
DOP54: Real-world effectiveness of thiopurine monotherapy in Crohn’s Disease: Is there still a place for thiopurines in the biological era?
Year: 2021
Source: ECCO'21 Virtual
Authors: Rezazadeh Ardabili, A.(1,2);Jeuring, S.F.G.(1);Mujagic, Z.(1,2);Romberg-Camps, M.J.L.(3);van Bodegraven, A.A.(3);Jonkers, D.M.A.E.(1,2);Pierik, M.J.(1,2)
Created: Wednesday, 2 June 2021, 4:12 PM
DOP54: Time to effect of biologics and small molecules for patients with moderately to severely active luminal Crohn's disease – a systematic review and network meta-analysis
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Attauabi, M.(1,2)*;Steenholdt, C.(1);Burisch, J.(2,3);Gubatan, J.(4);Nielsen, O.H.(1);Seidelin, J.B.(1);
Created: Friday, 14 July 2023, 10:43 AM
DOP55 A real-world comparison of the effectiveness and safety of vedolizumab and anti-TNF therapies in early treatment initiation with first-line biologic therapy in ulcerative colitis: Results from EVOLVE
Year: 2020
Source:

ECCO'20 Vienna

Authors:

G. Mantzaris1, B. Bressler2, U. Kopylov3, M. Bassel4, N. Brett4, C. Colby5, C. Lopez6, S. Saha7, C. Kifnidi8, C. Agboton9, S. Adsul9, D. Demuth10, M. Luo11, S. Wang11, A. Yarur12

Created: Thursday, 30 January 2020, 10:12 AM
DOP55: ZNF133 is associated with infliximab responsiveness in patients with inflammatory bowel diseases using whole-exome sequencing
Year: 2019
Source: ECCO'19 Copenhagen
Authors: Eun Suk Jung
Created: Tuesday, 28 May 2019, 3:32 PM
Anti-TNF agents, Infliximab, Pharmacogenetics
Files: 1
DOP55: High diagnostic accuracy of 4-probe methylation biomarkers in paediatric Inflammatory Bowel Disease by epigenome-wide analysis
Year: 2024
Source: ECCO'24 Stockholm
Authors: Noble, Alexandra
Created: Tuesday, 30 April 2024, 5:03 PM
DOP55: Histopathological features at diagnosis to predict long-term disease course of Crohn’s Disease
Year: 2021
Source: ECCO'21 Virtual
Authors: Rezazadeh Ardabili, A.(1,2);Goudkade, D.(3);Wintjens, D.S.J.(1,2);Romberg-Camps, M.J.L.(4);Winkens, B.(5);Pierik, M.J.(1,2);Grabsch, H.I.(6,7);Jonkers, D.M.A.E.(1,2)
Created: Wednesday, 2 June 2021, 4:12 PM
DOP55: Long-term outcomes after histologic-endoscopic mucosal healing: Results from the UNIFI study in Ulcerative Colitis
Year: 2022
Source: ECCO'22
Authors: Leong, R.(1);Sands, B.(2);Peyrin-Biroulet, L.(3);Marano, C.(4);Miao, Y.(4);Izanec, J.(5);Feagan, B.(6);Rubin, D.(7); UNIFI Investigators
Created: Friday, 11 February 2022, 3:52 PM
DOP55: The increasing burden of direct and indirect costs of IBD
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Johan Burisch
Created: Friday, 14 July 2023, 2:22 PM
DOP55: The increasing burden of direct and indirect costs of IBD
Year: 2023
Source: ECCO’23 Copenhagen
Authors: BurischPhD, J.(1)*;
Created: Friday, 14 July 2023, 10:43 AM
DOP55: ZNF133 is associated with infliximab responsiveness in patients with inflammatory bowel diseases using whole-exome sequencing
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

E. S. Jung*1,2, K-w. Choi3, S. W. Kim2, M. Hübenthal1, S. Mucha1, J. Park2, Z. Park3, D. Ellinghaus1, S. Schreiber1, A. Franke1, W. Y. Oh3, J. H. Cheon2

Created: Friday, 22 February 2019, 9:41 AM
DOP56 Ustekinumab maintained clinically meaningful improvement in health-related quality of life in patients with moderate to severe ulcerative colitis: Results from the UNIFI long-term extension
Year: 2020
Source:

ECCO'20 Vienna

Authors:

W.J. Sandborn1, D.S. Rowbotham2, R.W.L. Leong3, C. Han4, Y. Zhou5, H. Zhang5, J. Johanns5, C. Marano6, S. Danese7, UNIFI Investigators

Created: Thursday, 30 January 2020, 10:12 AM
DOP56: Dashboard driven vs. conventional dosing of infliximab in inflammatory bowel disease patients: the PRECISION trial
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

A. Strik*1,2, S. Berends3, D. Mould4, R. Mathôt3, C. Ponsioen2, J. van den Brande5, J. Jansen6, D. Hoekman7, J. Brandse8, M. Löwenberg2, G. D'Haens2

Created: Friday, 22 February 2019, 9:41 AM
DOP56: Fibrosis-related transcriptome unveils a distinctive matrix remodelling pattern in penetrating but not in stricturing ileal Crohn's Disease
Year: 2024
Source: ECCO'24 Stockholm
Authors: Tavares de Sousa, Helena
Created: Tuesday, 30 April 2024, 5:03 PM